Mebendazole and Gastric Cancer Research: What Patients Should Know

By Tom Siegenthaler, DPh, RPh, FACA

Gastric cancer, also known as stomach cancer, is a serious disease that is often diagnosed at an advanced stage. Because symptoms may be vague or minimal early on, many patients do not receive a diagnosis until the cancer has already progressed.

Treatment for gastric cancer may include surgery, chemotherapy, radiation therapy, immunotherapy, targeted therapy, or a combination of approaches. Outcomes can vary widely based on stage, tumor biology, overall health, and treatment response.

Because advanced gastric cancer can be difficult to treat, researchers continue to study new strategies, including the potential role of repurposed medications.

What Is Mebendazole?

Mebendazole, often called MBZ, is an older prescription medication traditionally used to treat certain parasitic infections. It has been used for decades for its approved indications and has an established safety profile when used appropriately.

In recent years, mebendazole has gained attention in cancer research because some laboratory and early clinical studies have explored whether it may affect cancer-related pathways.

This does not mean mebendazole is approved as a cancer treatment. It means researchers are studying whether an existing medication may have potential uses beyond its original purpose.

Why Researchers Study Repurposed Drugs

Drug repurposing is the process of studying existing medications for possible new uses. In cancer research, repurposed drugs may be evaluated because they could influence pathways involved in:

• Cancer cell growth
• Cell division
• Tumor spread
• Treatment resistance
• Inflammatory signaling
• Cancer cell survival

Repurposed drug research can be promising, but it requires careful clinical evaluation before any medication can be considered safe or effective for a new use.

Mebendazole and Gastric Cancer Research

Laboratory studies have explored mebendazole in relation to gastric cancer cells. Some research suggests mebendazole may affect cancer cell proliferation, microtubule structure, invasion, and growth behavior in certain experimental models.

These findings are scientifically interesting, but they do not prove that mebendazole treats gastric cancer in patients.

Research involving cell lines, animal models, or limited case reports is not the same as large clinical trials. More evidence is needed to determine whether mebendazole has a meaningful role in gastric cancer care.

Mebendazole and Other Cancer Research

Mebendazole has also been studied in other cancer research areas, including colorectal cancer and certain solid tumors. Some reports have described individual patient responses, but case reports cannot predict how another patient will respond.

Cancer treatment decisions should always be individualized and guided by an oncology team.

Important Safety Considerations

Even medications with a long history of approved use can carry risks when used off-label, at different doses, or for longer periods.

Potential safety considerations with mebendazole may include:

• Liver function changes
• Drug interactions
• Gastrointestinal side effects
• Blood count changes
• Pregnancy and breastfeeding concerns
• Interactions with cancer therapies

Patients should never start mebendazole for cancer-related purposes without the direct involvement of their oncologist or qualified healthcare provider.

Off-Label Use Requires Medical Supervision

Off-label use means a medication is being used for a condition, dose, or route that is not specifically approved by the FDA. Off-label prescribing can be appropriate in some situations, but it must be based on clinical judgment and patient-specific factors.

For cancer patients, this is especially important.

An oncology team can evaluate:

• Cancer type and stage
• Current treatment plan
• Lab results
• Liver and kidney function
• Medication interactions
• Treatment goals
• Available clinical evidence
• Risks and potential benefits

A Pharmacist’s Role in Medication Safety

Pharmacists can support patients and providers by reviewing medication safety, possible interactions, dosing concerns, and prescription questions.

For patients interested in repurposed drug research, pharmacist involvement can help ensure that conversations remain grounded in safety and provider-guided care.

Final Takeaway

Mebendazole is an older medication that has been studied in cancer research, including gastric cancer models. While this research is important, mebendazole is not an FDA-approved cancer treatment and should not replace oncology care.

Patients interested in mebendazole or other repurposed medications should speak directly with their oncologist before making any treatment decisions.